For patients with stage III or IV Hodgkin lymphoma, nivolumab with doxorubicin, vinblastine, and dacarbazine (N+AVD) yields ...

An immunotherapy approach to treating advanced Hodgkin lymphoma may drastically increase patients’ chances of survival, ...

Adding nivolumab (Opdivo) instead of brentuximab vedotin (Adcetris) to the standard chemotherapy backbone of doxorubicin ...

In mid-2023, the SWOG S1826 phase 3 trial in advanced Hodgkin lymphoma reported highly positive primary results earlier than expected, after the trial’s second planned interim analysis found the ...

The U.S. Food and Drug Administration has approved Itovebi (inavolisib), in combination with palbociclib (Ibrance) and ...

Bank of America Securities analyst Jason Gerberry has reiterated their bullish stance on JAZZ stock, giving a Buy rating today. Jason Gerberry ...

Treatment with cediranib or cediranib plus olaparib is not superior to standard of care (SOC) in patients with platinum-resistant or -refractory epithelial ovarian cancer, according to results from a ...

Shares of Jazz Pharmaceuticals are trading only slightly higher in the last few weeks despite two unexpected wins. Explore ...

Primary outcomes were progression-free survival, assessed by blinded independent central review, and overall survival in the full analysis set. Participants were randomly assigned (1:1) to receive ...

"The high rate of progression-free survival with Nivolumab ? AVD represents another paradigm shift incorporating immunotherapy into the frontline treatment of advanced stage classic Hodgkin Lymphoma ...